标题
Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
作者
关键词
-
出版物
Frontiers in Immunology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-12-21
DOI
10.3389/fimmu.2021.800879
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors
- (2021) Kevin Tyan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
- (2021) Luis Paz-Ares et al. LANCET ONCOLOGY
- Safety and efficacy of combination therapy using programmed cell death protein‐1/programmed cell death ligand‐1 inhibitors and radiotherapy in patients with non‐small‐cell lung cancer: A systematic review and meta‐analysis
- (2021) Yichao Geng et al. Cancer Medicine
- Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis
- (2021) Fangwen Zou et al. Journal for ImmunoTherapy of Cancer
- A case of immune checkpoint inhibitor‐associated gastroenteritis detected by ultrasonography
- (2021) Satomi Omotehara et al. JOURNAL OF CLINICAL ULTRASOUND
- Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors
- (2021) Anusha S. Thomas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review
- (2021) Stratigoula Sakellariou et al. BMC GASTROENTEROLOGY
- Biomarkers of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer: Beyond PD-L1
- (2021) Luis Cabezón-Gutiérrez et al. Clinical Lung Cancer
- Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options
- (2021) Carmen Portenkirchner et al. Pharmaceuticals
- C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting
- (2021) Justine Lauwyck et al. MELANOMA RESEARCH
- A case of immune checkpoint inhibitor-related colitis with a distinctive endoscopic finding of colonic pseudolipomatosis
- (2021) Tatsushi Naito et al. Clinical Journal of Gastroenterology
- Checkpoint Inhibitor–Induced Colitis
- (2020) Emanuelle Bellaguarda et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
- (2020) N. Chaput et al. ANNALS OF ONCOLOGY
- Association of vitamin D intake with decreased risk of immune checkpoint inhibitor-induced colitis.
- (2020) Kevin Tyan et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma
- (2020) Sarah Abou Alaiwi et al. Journal for ImmunoTherapy of Cancer
- Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer
- (2020) Maria Jove et al. Translational Lung Cancer Research
- Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy
- (2020) Pallavi A. Patil et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Immune-related Pneumonitis Following Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer
- (2020) Jarushka Naidoo et al. Clinical Lung Cancer
- Leucine-Rich α2-Glycoprotein as a Potential Biomarker for Immune-related Colitis After Anti–PD-L1 Therapy: A Report of a Case Series
- (2020) Katsuhiro Yoshimura et al. Clinical Lung Cancer
- Immune checkpoint inhibitors re-challenge efficacy in non-small-cell lung cancer patients
- (2020) Elisa Gobbini et al. Clinical Lung Cancer
- Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer
- (2020) Vickie R. Shannon CURRENT OPINION IN PULMONARY MEDICINE
- Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
- (2020) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Switching administration of anti‐PD ‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review
- (2020) Shingo Kitagawa et al. Thoracic Cancer
- Opportunistic bowel infection after corticosteroid dosage tapering in a stage IV lung cancer patient with tislelizumab‐related colitis
- (2020) Jun Ni et al. Thoracic Cancer
- Immune-related adverse events of checkpoint inhibitors
- (2020) Manuel Ramos-Casals et al. Nature Reviews Disease Primers
- Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
- (2020) Charles Dolladille et al. JAMA Oncology
- Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis
- (2020) Shilpa Grover et al. CANCER
- Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
- (2020) Adrienne M. Luoma et al. CELL
- Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis
- (2020) Yukie Hayashi et al. DIGESTIVE DISEASES AND SCIENCES
- Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
- (2020) Jordi Remon et al. Journal of Thoracic Oncology
- Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
- (2020) John Haanen et al. Journal for ImmunoTherapy of Cancer
- Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma
- (2020) David M Favara et al. ESMO Open
- Management of immunotherapy colitis: Special considerations in the COVID‐19 era
- (2020) Shilpa Grover et al. CANCER
- Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor–induced gastroenterocolitis
- (2020) Leah L. Thompson et al. EUROPEAN JOURNAL OF CANCER
- AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor (ICI) Colitis and Hepatitis: Expert Review
- (2020) Michael Dougan et al. GASTROENTEROLOGY
- Efficacy and outcome of Tofacitinib in Immune checkpoint inhibitor colitis.
- (2020) Shrinivas Bishu et al. GASTROENTEROLOGY
- Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer
- (2020) Adi Kartolo et al. JOURNAL OF IMMUNOTHERAPY
- Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review
- (2020) Peter L. Miller et al. Gut Pathogens
- Management of Immune Checkpoint Inhibitor Toxicities
- (2020) Quentin Durrechou et al. Cancer Management and Research
- Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
- (2020) Giuseppe Lamberti et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
- (2020) Marion Allouchery et al. Journal for ImmunoTherapy of Cancer
- Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy
- (2020) Ying-Chun Lo et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Gut microbiome and checkpoint inhibitor colitis
- (2020) Kanika Sehgal et al. Intestinal Research
- Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma
- (2019) Hamzah Abu-Sbeih et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
- (2019) Filipe Martins et al. LANCET ONCOLOGY
- Immune checkpoint inhibitor-induced colitis: A comprehensive review
- (2019) Aniruddh Som et al. World Journal of Clinical Cases
- Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
- (2019) Hao Chi Zhang et al. Journal for ImmunoTherapy of Cancer
- Flexible Sigmoidoscopy Rather than Colonoscopy Is Adequate for the Diagnosis of Ipilimumab-Associated Colitis
- (2019) J. Daniel Herlihy et al. SOUTHERN MEDICAL JOURNAL
- Nivolumab-Induced Fulminant Immune-Related Colitis Despite Infliximab in a Patient With NSCLC
- (2019) Rutger Callens et al. Journal of Thoracic Oncology
- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis
- (2019) Andrew P. Wright et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Case report: reinitiating pembrolizumab treatment after small bowel perforation
- (2019) Tim N. Beck et al. BMC CANCER
- Nivolumab plus ipilimumab in non-small-cell lung cancer
- (2019) Martin Reck et al. Future Oncology
- Superimposed Clostridium difficile Infection During Checkpoint Inhibitor Immunotherapy-induced Colitis
- (2019) Nalan A. Babacan et al. JOURNAL OF IMMUNOTHERAPY
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
- (2019) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Immune‐Related Adverse Events in the Gastrointestinal Tract: Diagnostic Utility of Upper Gastrointestinal Biopsies
- (2019) M. Lisa Zhang et al. HISTOPATHOLOGY
- Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
- (2019) Hamzah Abu-Sbeih et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Implications of Co-Occurring Dermatologic and Gastrointestinal Toxicity from Immune Checkpoint Inhibition Therapy for Advanced Malignancies: A Retrospective Cohort Study
- (2019) Gabriel E. Molina et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Targeting immune cell circuits and trafficking in inflammatory bowel disease
- (2019) Markus F. Neurath NATURE IMMUNOLOGY
- Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach
- (2019) Zia Khan et al. Genome Medicine
- Probiotics Lactobacillus reuteri Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells
- (2019) Tingting Wang et al. Frontiers in Immunology
- Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
- (2019) Audrey Simonaggio et al. JAMA Oncology
- “Immune checkpoint inhibitor-related luminal GI adverse events”
- (2019) Paul T. Kröner et al. GASTROINTESTINAL ENDOSCOPY
- Combination therapy with PD-1 or PD-L1 inhibitors for cancer
- (2019) Hidetoshi Hayashi et al. International Journal of Clinical Oncology
- C-reactive protein as an early marker of immune-related adverse events
- (2019) Amir-Reza Abolhassani et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells
- (2019) Ronald Anderson et al. Frontiers in Immunology
- Acute coronary syndrome and recurrent colitis as immune-related adverse events in a lung cancer patient
- (2019) Bárbara Cancela-Díez et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events
- (2019) Yousef R. Badran et al. Journal for ImmunoTherapy of Cancer
- Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
- (2019) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports
- (2019) Koji Yoshino et al. BMC CANCER
- Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
- (2019) Ken Masuda et al. BMC CANCER
- Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules
- (2019) Xin Lin et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Budesonide treatment for microscopic colitis from immune checkpoint inhibitors
- (2019) Michael S. Hughes et al. Journal for ImmunoTherapy of Cancer
- Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy
- (2019) Yi-He Liu et al. BIOMEDICINE & PHARMACOTHERAPY
- Parathyroid hormone related protein (PTHrP)-mediated hypercalcemia in malignancy associated with anti-PD-1 immune checkpoint inhibitor treatment and related inflammatory reactions
- (2019) Maria V. Deligiorgi et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
- (2019) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis
- (2019) Matteo Giaj Levra et al. LUNG CANCER
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J B A G Haanen et al. ANNALS OF ONCOLOGY
- High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
- (2018) Alexander T. Faje et al. CANCER
- Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
- (2018) Katharina C. Kähler et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
- (2018) Ryuma Tokunaga et al. CANCER TREATMENT REVIEWS
- The impact of the intestinal microbiota in therapeutic responses against cancer
- (2018) Anne-Gaëlle Goubet et al. COMPTES RENDUS BIOLOGIES
- Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1
- (2018) Ahmed Mekki et al. EUROPEAN JOURNAL OF CANCER
- Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
- (2018) Yinghong Wang et al. INFLAMMATORY BOWEL DISEASES
- Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer
- (2018) Yuichiro Yasuda et al. INTERNAL MEDICINE
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective
- (2018) Dipti M Karamchandani et al. JOURNAL OF CLINICAL PATHOLOGY
- Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
- (2018) Xiaolei Li et al. Journal of Hematology & Oncology
- The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy
- (2018) Parul Tandon et al. JOURNAL OF IMMUNOTHERAPY
- Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis
- (2018) B. L. Adler et al. JOURNAL OF INTERNAL MEDICINE
- Brief report: Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab
- (2018) Susan Combs Scott et al. Journal of Thoracic Oncology
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Lactobacillus reuteri in Human Health and Diseases
- (2018) Qinghui Mu et al. Frontiers in Microbiology
- Safety and Efficacy of Retreating with Immunotherapy After Immune-Related Adverse Events in Patients with NSCLC
- (2018) Fernando Costa Santini et al. Cancer Immunology Research
- The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1
- (2018) Lisa Derosa et al. OncoImmunology
- Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
- (2018) Yinghong Wang et al. Journal for ImmunoTherapy of Cancer
- The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review
- (2018) Ryosuke Yamauchi et al. BMC GASTROENTEROLOGY
- Checkpoint inhibitor colitis
- (2018) Spyros I. Siakavellas et al. CURRENT OPINION IN GASTROENTEROLOGY
- Enterocolitis due to immune checkpoint inhibitors: a systematic review
- (2018) Emilie Soularue et al. GUT
- Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?
- (2018) Kati Choi et al. INFLAMMATORY BOWEL DISEASES
- Immune Checkpoint Inhibitor-Associated Colits and Hepatitis
- (2018) Haritha G. Reddy et al. Clinical and Translational Gastroenterology
- Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
- (2018) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Immune dysregulation in cancer patients developing immune-related adverse events
- (2018) Shaheen Khan et al. BRITISH JOURNAL OF CANCER
- Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
- (2018) Su Y. Lim et al. CLINICAL CANCER RESEARCH
- Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
- (2018) Yinghong Wang et al. NATURE MEDICINE
- Clinical characterization of colitis arising from anti-PD-1 based therapy
- (2018) Daniel Y Wang et al. OncoImmunology
- Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
- (2018) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
- (2018) Daniel H Johnson et al. Journal for ImmunoTherapy of Cancer
- Mycophenolate mofetil alongside high-dose corticosteroids
- (2018) Romaana Mir et al. MELANOMA RESEARCH
- Immune modulator-induced changes in the gastrointestinal tract
- (2017) Prashant Bavi et al. HISTOPATHOLOGY
- Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease
- (2017) H. Matthew Cohn et al. INFLAMMATORY BOWEL DISEASES
- Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancer
- (2017) Tomoyoshi Takenaka et al. INVESTIGATIONAL NEW DRUGS
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
- (2017) Mario Sznol et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities
- (2017) Clélia Coutzac et al. Journal of Crohns & Colitis
- Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab
- (2017) Yasuhiro Fujisawa et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Bifidobacteriumcan mitigate intestinal immunopathology in the context of CTLA-4 blockade
- (2017) Feng Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immune mediated colitis caused by lung cancer treatment with atezolizumab
- (2017) Santiago González Vázquez et al. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Immune checkpoint inhibitor colitis: the flip side of the wonder drugs
- (2017) Naziheh Assarzadegan et al. VIRCHOWS ARCHIV
- Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis
- (2017) Animesh Jain et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients
- (2017) Marlene Garcia-Neuer et al. Cancer Immunology Research
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
- (2017) Vivek Kumar et al. Frontiers in Pharmacology
- Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
- (2017) Michael Dougan Frontiers in Immunology
- Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis
- (2017) Daniel Y. Wang et al. OncoImmunology
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Biomarkers associated with checkpoint inhibitors
- (2016) G. Manson et al. ANNALS OF ONCOLOGY
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Infliximab for ipilimumab-induced colitis: A series of 13 patients
- (2016) Nadine T Hillock et al. Asia-Pacific Journal of Clinical Oncology
- Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
- (2016) S Bowyer et al. BRITISH JOURNAL OF CANCER
- Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome
- (2016) J. M. Pitt et al. CANCER RESEARCH
- Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis
- (2016) Eduard Cornelis Verschuren et al. Clinical Gastroenterology and Hepatology
- Checkpoint inhibitors and gastrointestinal immune-related adverse events
- (2016) Simon Pernot et al. CURRENT OPINION IN ONCOLOGY
- Protective role of G-CSF in dextran sulfate sodium-induced acute colitis through generating gut-homing macrophages
- (2016) Shahab Meshkibaf et al. CYTOKINE
- PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’
- (2016) Raul S Gonzalez et al. HISTOPATHOLOGY
- P-011 Gastrointestinal Adverse Effects of Immunomodulation
- (2016) Bilal Gondal et al. INFLAMMATORY BOWEL DISEASES
- Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
- (2016) Katharina C. Kähler et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
- (2016) L. Marthey et al. Journal of Crohns & Colitis
- Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology
- (2016) Lindsey Robert Baden et al. Journal of the National Comprehensive Cancer Network
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
- (2016) Scott Antonia et al. LANCET ONCOLOGY
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- Anti-PD1-induced collagenous colitis in a melanoma patient
- (2016) Barouyr Baroudjian et al. MELANOMA RESEARCH
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
- (2016) Katrin Klocke et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
- (2016) Claire F. Friedman et al. JAMA Oncology
- Systematic review: colitis associated with anti-CTLA-4 therapy
- (2015) A. Gupta et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Ipilimumab associated colitis: An IpiColitis case series at MedStar Georgetown University Hospital
- (2015) Pawan Rastogi WORLD JOURNAL OF GASTROENTEROLOGY
- PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
- (2015) Nikolaos Patsoukis et al. Nature Communications
- Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
- (2015) S. H. Tirumani et al. Cancer Immunology Research
- Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis
- (2015) Andrew R. Barina et al. Abdominal Radiology
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
- (2015) Ahmad A. Tarhini et al. Journal for ImmunoTherapy of Cancer
- Role of the Microbiota in Immunity and Inflammation
- (2014) Yasmine Belkaid et al. CELL
- Plasmacytoid Dendritic Cells Mediate Anti-inflammatory Responses to a Gut Commensal Molecule via Both Innate and Adaptive Mechanisms
- (2014) Suryasarathi Dasgupta et al. Cell Host & Microbe
- Protective effects of Fc-fused PD-L1 on two different animal models of colitis
- (2014) Mi-Young Song et al. GUT
- Focused specificity of intestinal TH17 cells towards commensal bacterial antigens
- (2014) Yi Yang et al. NATURE
- Ipilimumab-Associated Colitis: CT Findings
- (2013) Kyung Won Kim et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Histologic Features in Colon Biopsies Can Discriminate Mycophenolate From GVHD-induced Colitis
- (2013) Kremena V. Star et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis
- (2013) Ashwin N. Ananthakrishnan ANNALS OF INTERNAL MEDICINE
- Ipilimumab-induced Perforating Colitis
- (2013) Kisha A. Mitchell et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
- (2013) Vafa Shahabi et al. Journal of Translational Medicine
- PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2
- (2013) Nikolaos Patsoukis et al. MOLECULAR AND CELLULAR BIOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria
- (2012) M J Barnes et al. Mucosal Immunology
- The human commensal Bacteroides fragilis binds intestinal mucin
- (2011) Julie Y. Huang et al. ANAEROBE
- Lymphocytic Colitis Secondary to Ipilimumab Treatment
- (2011) Alejandro García-Varona et al. INFLAMMATORY BOWEL DISEASES
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
- (2011) O. S. Qureshi et al. SCIENCE
- The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications
- (2010) Anna Maria Di Giacomo et al. SEMINARS IN ONCOLOGY
- Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management
- (2010) Katharina C. Kaehler et al. SEMINARS IN ONCOLOGY
- Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
- (2009) James D. Lord et al. DIGESTIVE DISEASES AND SCIENCES
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
- (2008) R. L. Johnston et al. DIGESTIVE DISEASES AND SCIENCES
- A microbial symbiosis factor prevents intestinal inflammatory disease
- (2008) Sarkis K. Mazmanian et al. NATURE
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now